BRPI0812366A2 - composto, composição farmacêutica e métodos de modulação de um ou mais subtipos de gabaa, de tratamento de deficiência orgânica cognitiva e de desordem psiquiátrica e aumento de função cognitiva em animal e usos do composto ou da composição. - Google Patents

composto, composição farmacêutica e métodos de modulação de um ou mais subtipos de gabaa, de tratamento de deficiência orgânica cognitiva e de desordem psiquiátrica e aumento de função cognitiva em animal e usos do composto ou da composição.

Info

Publication number
BRPI0812366A2
BRPI0812366A2 BRPI0812366A BRPI0812366A BRPI0812366A2 BR PI0812366 A2 BRPI0812366 A2 BR PI0812366A2 BR PI0812366 A BRPI0812366 A BR PI0812366A BR PI0812366 A BRPI0812366 A BR PI0812366A BR PI0812366 A2 BRPI0812366 A2 BR PI0812366A2
Authority
BR
Brazil
Prior art keywords
compound
composition
modulating
gabaa
methods
Prior art date
Application number
BRPI0812366A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan P Kaplan
Jan W F Wasley
Varsha Gupta
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of BRPI0812366A2 publication Critical patent/BRPI0812366A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0812366A 2007-06-08 2008-06-06 composto, composição farmacêutica e métodos de modulação de um ou mais subtipos de gabaa, de tratamento de deficiência orgânica cognitiva e de desordem psiquiátrica e aumento de função cognitiva em animal e usos do composto ou da composição. BRPI0812366A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94300507P 2007-06-08 2007-06-08
PCT/US2008/066201 WO2008154438A1 (en) 2007-06-08 2008-06-06 Therapeutic pyrazoloquinoline derivatives

Publications (1)

Publication Number Publication Date
BRPI0812366A2 true BRPI0812366A2 (pt) 2016-08-02

Family

ID=40096440

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812366A BRPI0812366A2 (pt) 2007-06-08 2008-06-06 composto, composição farmacêutica e métodos de modulação de um ou mais subtipos de gabaa, de tratamento de deficiência orgânica cognitiva e de desordem psiquiátrica e aumento de função cognitiva em animal e usos do composto ou da composição.

Country Status (13)

Country Link
US (2) US7872002B2 (cg-RX-API-DMAC7.html)
EP (1) EP2166852B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010529143A (cg-RX-API-DMAC7.html)
KR (1) KR20100039331A (cg-RX-API-DMAC7.html)
CN (1) CN101742908A (cg-RX-API-DMAC7.html)
AT (1) ATE544344T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008261884A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0812366A2 (cg-RX-API-DMAC7.html)
CA (1) CA2688395A1 (cg-RX-API-DMAC7.html)
ES (1) ES2386168T3 (cg-RX-API-DMAC7.html)
IL (1) IL202270A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009013202A (cg-RX-API-DMAC7.html)
WO (1) WO2008154438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2688405A1 (en) * 2007-06-08 2008-12-18 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline urea derivatives
CN101754681A (zh) * 2007-06-08 2010-06-23 海利空医疗公司 治疗用吡唑并萘啶衍生物
EP2166852B1 (en) * 2007-06-08 2012-02-08 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline derivatives
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
JP2018537450A (ja) * 2015-11-16 2018-12-20 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ Ｄｎａメチルトランスフェラーゼ阻害剤としての新規化合物
CN105294648B (zh) * 2015-11-30 2017-11-28 山东罗欣药业集团股份有限公司 一种西他沙星的制备方法
WO2022037631A1 (zh) * 2020-08-21 2022-02-24 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3204126A1 (de) * 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4814450A (en) 1984-07-09 1989-03-21 Ciba-Geigy Corporation Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
JPS61112075A (ja) 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
EP0214092A1 (en) 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5334595A (en) 1992-10-23 1994-08-02 Sterling Winthrop Inc. Pyrazoloquinolones as anticancer agents
GB9716347D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
GB0108475D0 (en) * 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
JP3896309B2 (ja) 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体
US7674906B2 (en) 2002-12-16 2010-03-09 Active Biotech Ab Tetracyclic immunomodulatory compounds
US20050245563A1 (en) 2003-05-29 2005-11-03 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2621560A1 (en) 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
JP2008047893A (ja) * 2006-08-11 2008-02-28 Samsung Electronics Co Ltd 薄膜トランジスタ表示板及びその製造方法
EP2166852B1 (en) * 2007-06-08 2012-02-08 Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline derivatives

Also Published As

Publication number Publication date
KR20100039331A (ko) 2010-04-15
MX2009013202A (es) 2010-04-09
EP2166852A1 (en) 2010-03-31
US8598159B2 (en) 2013-12-03
US7872002B2 (en) 2011-01-18
AU2008261884A1 (en) 2008-12-18
IL202270A0 (en) 2010-06-16
US20110065693A1 (en) 2011-03-17
JP2010529143A (ja) 2010-08-26
HK1142775A1 (en) 2010-12-17
WO2008154438A1 (en) 2008-12-18
CA2688395A1 (en) 2008-12-18
ES2386168T3 (es) 2012-08-10
EP2166852B1 (en) 2012-02-08
ATE544344T1 (de) 2012-02-15
CN101742908A (zh) 2010-06-16
EP2166852A4 (en) 2010-07-07
US20080306049A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
BRPI0812366A2 (pt) composto, composição farmacêutica e métodos de modulação de um ou mais subtipos de gabaa, de tratamento de deficiência orgânica cognitiva e de desordem psiquiátrica e aumento de função cognitiva em animal e usos do composto ou da composição.
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
BRPI0508820B8 (pt) compostos moduladores de receptor de opióide e composição que os compreende
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA201001371A1 (ru) Конденсированные пиримидиноновые соединения как модуляторы trpv3
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MX2009013205A (es) Derivados de pirazoloquinolina urea terapeuticos.
BRPI0412809A (pt) compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
DE602007006328D1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
ATE432279T1 (de) Tricyclische delta-opioid-modulatoren
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
BRPI0412868A (pt) compostos de sulfonildihidroimidazopiridinona como ligantes da 5-hidroxitriptamina-6
EA201390055A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОПИРАЗОЛО[3,4-b]АЗЕПИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНЫХ ГЛУТАМАТНЫХ РЕЦЕПТОРОВ
TW200740766A (en) Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6-ligands
BRPI0507763A (pt) moduladores de receptor seletivo do subtipo gaba-a heterocìclicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.